Loading clinical trials...
Loading clinical trials...
Advancing the Understanding of Pain Mechanisms in Inflammatory Arthritis Towards Precision Pain Management
Our primary objective is to better understand the etiology and consequences of chronic paint by using an explorative approach to identify phenotypes and endotypes of patients with inflammatory arthritis, with a special focus on central sensitization and cognitive functioning as a key element in chronic pain. We will also examine the risk factors and clinical impact of these factors on pain, disease activity and treatment effects in a longitudinal study of patients with inflammatory joint disesases.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Start Date
August 1, 2025
Primary Completion Date
November 1, 2027
Completion Date
November 1, 2027
Last Updated
May 23, 2025
350
ESTIMATED participants
Biological or targeted synthetic DMARD
DRUG
Lead Sponsor
Diakonhjemmet Hospital
Collaborators
NCT07484243
NCT01422694
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions